Completed PHASE4 INTERVENTIONAL 4-arm NCT01721291

Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)

Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD)

Sponsor: Imperial College London

Conditions ASTHMA CHRONIC OBSTRUCTIVE PULMONARY DISEASE HEALTHY SUBJECTS

Interventions SALBUTAMOL

Updated 7 times since 2017 Last updated: May 26, 2022 Started: Oct 1, 2012 Primary completion: Nov 27, 2017 Completion: Nov 27, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01721291, this PHASE4 trial focuses on ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE and remains completed. Sponsored by Imperial College London, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Apr 2023 — Jul 2024 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jan 2021 — Apr 2023 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4

▶ Show 2 earlier versions

Sep 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

Status: Active Not Recruiting → Unknown Status
Jan 2017 — Sep 2017 [monthly]

Active Not Recruiting PHASE4

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Imperial College London
National Institute for Health Research, United Kingdom

Data source: Imperial College London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom